GlassScriptPhysician profile
Brian Jacover
NPI 1417124769
$508.25
in general payments reported to CMS, 2019-2025
14 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $34.50 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.37 | 2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $54.73 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $47.97 | 2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $47.08 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $43.71 | 2025 | Auvelity |
| Exact Sciences Corporation | $43.61 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $34.50 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $27.92 | 2025 | Mounjaro |
| Abbvie INC. | $25.29 | 2025 | |
| Radius Health, INC. | $23.55 | 2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $21.64 | 2025 | |
| Glaxosmithkline, LLC. | $20.90 | 2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.54 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $14.44 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jacover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.